ADAP

SVB Securities analyst Jonathan Chang reiterated a Hold rating on Adaptimmune Therapeutics (ADAP - Research Report) on November 8 and set a price target of $3.00. The company's shares closed yesterday at $2.10.Chang covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, Adaptimmune Therapeutics, and Immatics. According to TipRanks, Chang has an average return of -14.4% and a 24.72% success rate on recommended stocks. Adaptimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.70, a 171.43% upside from current levels. In a report released on October 25, Mizuho Securities also maintained a Hold rating on the stock with a $9.00 price target.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-their-hold-rating-for-adaptimmune-therapeutics-adap-3?utm_source=advfn.com&utm_medium=referral